Company intelligence / Profile preview

FEMSelect

Tel Aviv, Israelecosystem.freewayphx.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

FEMSelect (formerly POP Medical Solutions) developed EnPlace and NeuGuide™, both minimally invasive, mesh-free devices for pelvic organ prolapse repair. EnPlace has FDA clearance and CE Mark; NeuGuide™ also received FDA clearance. Clinical studies have shown minimal pain and rapid recovery for patients, with over 3,000 procedures performed to date[3][4][6].

Therapeutic areas: Women's Health
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

LiNA Medical USA (US commercialization partner)[3]

Beyond the preview

Go deeper on FEMSelect.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FEMSelect.

Explore the full profile